Cord Blood America Starts Vegas Operation

Cord Blood America was founded seven years ago in Southern California, with funding from Credit Card, CBAI now claims to have one of the largest stem cell cryogenic storage facilities in the nation.  CBAI recently acquired CorCell, “the first licensed private cord blood bank in the United States.”

Most people will remember stem cells for the great promise they hold for medicine, and the controversy over taking them from embryos. However, the stem cells at CBAI (and other cord blood banks) are taken from umbilical cords at birth.

 On 22nd Januavary they started their operation  in Las Vegas.  CBAI occupies a modern-looking 17,000 square-foot building just a short block south of East Sunset Road. During the ribbon cutting ceremony, there were short speeches by CBAI board member Joseph R. Vicente; Somer Hollingsworth, who is President and CEO of the Nevada Development Authority, working to bring economic diversity to Las Vegas; Nevada Lieutenant Governor Brian Krolicky; CBAI Lab Director Dr. Geoffrey O’Neill; and Matthew Schissler, CEO and co-founder of CBAI, who talked about the growth of the company over the past seven years.  Dr. O’Neill is the lab director who once worked with Robert A. Good who was the first physician to perform a successful human bone marrow transplant.

Cord Blood America Storage

Cord Blood America Storage

Stem cells from cord blood can be beneficial for the child, can also be useful for the parents or relatives, and the possibilities don’t stop there. Stem cells may also be used for treating other people when the tissue type matches the recipient.  The collected Cord  Blood is stored in different liquid nitrogen storage tanks that can hold more than 20,000 samples each.  Each tank is insulated, and when the nitrogen level gets low the tank automatically sends a signal to the suppliers, in Los Angeles or Phoenix.

Cord Blood America Inc. (CBAI), through its wholly owned subsidiaries CorCell Companies Inc. and Cord Partners Inc., markets a patented service to preserve umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments. Cryogenically preserved umbilical cord stem blood is shown to be effective in the treatment of approximately 75 diseases.

Cryogenics is the freezing of live tissue or whole living organisms in order to defrost and bring them back to life at a later date. There are diseases that cannot be cured today and there is a theory about where some one may one day be kept on ice so to speak, while medical science works out how to cure the illness.

It may be a humble begining of another Amazon or eBay, who knows!

25 comments - What do you think?  Posted by admin - January 26, 2010 at 10:52 pm

Categories: Biotech Stock, Penny Stocks   Tags: , , , , ,

GenVec bags ASCO Foundation Merit Award

Research presented in the poster received a prestigious ASCO Foundation Merit Award. In addition, the poster received focused attention at the oral review session on esophageal cancer on January 22, 2010.

“This symposium brings together the greatest thought leaders in this area of oncology and we are pleased to be presenting this analysis at this event,” stated Mark Thornton, Ph.D., GenVec’s Senior Vice President of Product Development. “The encouraging increases in survival versus historical controls will warrant additional evaluation.”

The presented poster is available on GenVec’s website, www.genvec.com. To view the poster, click on “Investor Relations” then “Webcasts and Data.”

The poster, titled, “Long term survival analysis of multicenter clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of antitumor agent (TNFerade Biologic (TNF)) in patients with locally advanced esophageal cancer,” reports on updated efficacy and survival data. In the 24 patients receiving TNFerade in combination with chemoradiation, the median survival was 47.7 months.  Median survival from other historical clinical trials in similar stage disease ranged from 9.7 to 34 months.

Be the first to comment - What do you think?  Posted by admin - January 23, 2010 at 12:34 am

Categories: Biotech Stock   Tags: ,

Cord Blood America Interview

Cord Blood America Interview Video

Be the first to comment - What do you think?  Posted by admin - December 31, 2009 at 10:43 pm

Categories: Biotech Stock, Stock Trading   Tags: ,

SpongeTech Wash ‘N Wax 6-pack Combo Car Kit

SpongeTech Wash ‘N Wax 6-pack Combo Car Kit

Be the first to comment - What do you think?  Posted by admin - September 6, 2009 at 3:15 pm

Categories: Penny Stocks   Tags: , ,

Profiting From Penny Stock

Every body wanted to make money on the stock market, but the return on investing long term in blue chip stocks was low and takes years to get any decent amount. If you wanted to get returns on your investments faster and at a higher rate, Penny Stock is the option. By carefully watching penny stocks, you will understand that it makes amazing daily percentage gains.

Read more...

1 comment - What do you think?  Posted by admin - August 6, 2009 at 12:17 am

Categories: Penny Stocks, Stock Trading   Tags: , , , ,

« Previous PageNext Page »